Q & A

Antibody Manufacturing Perspectives: Miltenyi Biotec

BlueskyReddit
October 30, 2018
Jürgen Schmitz, Ph.D.
Chief Scientific Officer
Jürgen Schmitz, Ph.D.

Biocompare: What are the most important factors that a manufacturer should focus on when making an antibody?

JS: The antibody product must be highly specific, highly sensitive, and highly reproducible in all intended applications. The provider must take care that all these criteria are met. In addition, the vendor should describe exactly how the product is to be used. An antibody product is not per se highly specific and highly sensitive, but only in the context of proper use.

Biocompare: What aspect of your antibody manufacturing process are you most proud of?

JS: We are particularly proud of our REAfinity™ Recombinant Antibody portfolio. With more than 1,000 clones and more than 10,000 fluorochrome-conjugated antibodies, we offer by far the largest recombinant antibody portfolio for flow cytometry applications.

Biocompare: How does your company ensure the quality of the antibodies it produces?

JS: At Miltenyi Biotec we manufacture monoclonal antibodies mainly for cell isolation and flow cytometry applications. This means that we directly conjugate antibodies to magnetic beads or fluorochromes. When we develop a new antibody product for our portfolio, we rigorously evaluate its specificity and sensitivity in all target applications. Furthermore, we make sure that our manufacturing processes are highly consistent and that our quality control procedures ensure all critical quality attributes.

Biocompare: How do you ensure lot-to-lot consistency with your products?

JS: 

  • For more consistent manufacturing processes, we consequently make use of recombinant antibody technology instead of hybridoma technology. This is the basis for lot-to-lot consistency.
  • Recombinant expression, i.e. the expression of defined sequences in genetically modified organisms, not only enables better reproducibility, but also allows the targeted improvement of the antibody with regard to its application, for example the elimination of Fc receptor binding by mutations.
  • Also important for high reproducibility are consistent and robust conjugation processes. With our conjugation and purification procedures we make sure that the final product contains neither free fluorochromes, nor unconjugated antibodies or activation reagents, all of which could compromise antibody sensitivity in the final product.
  • Release testing for every batch includes an evaluation of purity, F/P ratio, sensitivity, specificity, and lot-to-lot consistency. For example, new lots of our flow cytometry antibodies are always tested against previous lots in a flow cytometry assay. If new batches do not meet defined criteria for mean fluorescence intensity (MFI), stain index (SI), target cell frequency, or other factors, such as background signal and staining pattern, in a given application, they are not released for sale.

Biocompare: What is your process for validating a given antibody for a specific application?

JS: At the end of the day, the antibody product has to do what it's supposed to do. This is tested during the development process as well as during the production of each batch. Of course, the tests depend on the application. Generally, we develop specific protocols for validation experiments and see if the results meet our pre-defined specifications. We routinely compare our products with those of our competitors, if there are any.

Biocompare: How does your company view the issue of antibody validation? Who is ultimately responsible for ensuring that scientific results are reproducible?

JS: 

  • At Miltenyi Biotec we think that all stakeholders are ultimately responsible for reproducibility. As an antibody manufacturer we see our primary responsibility in the development and implementation of consistent manufacturing processes and rigorous validation of the antibodies for their intended applications. This also means providing rigorously validated application protocols.
  • By using recombinant antibody technology instead of hybridoma technology, we have eliminated many causes for lack of reproducibility in antibody production.
  • We have recently launched campaigns on knock-out validations (specificity), clone comparisons (sensitivity), and lot-to-lot comparisons (reproducibility) to provide our customers with even more antibody validation data.
  • Apart from that we also offer hands-on trainings for our customers in our MACS® Academy in order to make sure antibodies are used correctly in their target applications.
  • Furthermore, we are a proud sponsor of the GBSI Antibody Validation Workshop as well as the the 2nd and 3rd International Antibody Validation Meetings.

Biocompare: How do you incorporate customer feedback into your processes?

JS: 

  • Feedback from customers is channeled through our sales employees or technical support right to the respective managers in R&D, Production, or QC. The responsible product managers take the lead for incorporating changes into the product pipeline. A good example for that is the recent adaptation of our antibody concentration. Nowadays, many customers need more concentrated flow cytometry antibodies as customers use multicolor panels with more than 8-10 colors. Therefore, we started reformatting our antibodies so that customers can use a total of 2 µL (titer 1:50) instead of 10 µL (titer 1:10) per test.
  • I can also encourage users to watch the testimonials we got from several researchers, describing the advantages of recombinant antibody technology and their experiences with our REAfinity Antibodies. 

Related Articles

Related Product Reviews

Comments